Evidence map›Paper›PMID 40600224›Full record

ReviewCancer diagnosis & prognosis

The Role of Axl Inhibition and Immune Checkpoint Blockade in Non-small Cell Lung Cancer: Current Understanding and Treatment Strategies.

Tae Woo Kim, Sung Hwan Kim, Hyun Ju DO, Young-Ah Suh, Daewon Jeong, Chuhee Lee

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tae Woo Kim *New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI Hub), Daegu, Republic of Korea.
Sung Hwan Kim *New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI Hub), Daegu, Republic of Korea.
Hyun Ju DONew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI Hub), Daegu, Republic of Korea.
Young-Ah SuhCenter for Advancing Cancer Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Daewon JeongLaboratory of Bone Metabolism and Control, Department of Microbiology, School of Medicine, Yeungnam University, Daegu, Republic of Korea.
Chuhee LeeDepartment of Biochemistry and Molecular Biology, School of Medicine, Yeungnam University, Daegu, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases and demonstrates limited responsiveness to traditional chemotherapy and radiation. Recent advancements in targeted therapies and immune checkpoint inhibitors (ICIs) have transformed NSCLC treatment, yet resistance mechanisms remain a challenge. Axl, a receptor tyrosine kinase over-expressed in NSCLC, drives tumor progression, epithelial-mesenchymal transition (EMT), and resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and ICIs. Preclinical studies highlight the efficacy of Axl inhibitors, such as bemcentinib, brigatinib, and enapotamab vedotin, in overcoming drug resistance and enhancing immune responses. Clinical trials combining Axl inhibitors with ICIs (

Indexed as

Axlchemoresistanceepidermal growth factor receptorimmune checkpoint inhibitors non-small cell lung cancerreviewtarget therapytyrosine kinase inhibitors

Identifiers

PMID40600224
PMCPMC12208208

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.